Immunovia discovery study published in top protein research journal
Immunovia (IMMNOV) announced the publication of its discovery study in the Journal of Proteome Research, marking it as the largest pancreatic cancer proteomics study to date. The study identified 41 protein biomarkers that strongly correlate with pancreatic ductal adenocarcinoma (PDAC). The research evaluated approximately 3,000 proteins in 329 blood samples from Stage I and II PDAC and non-PDAC matched control patients.
Five of these biomarkers were selected for Immunovia's next-generation test, which demonstrated excellent sensitivity and specificity in detecting early-stage pancreatic cancer. The company plans to launch this test for high-risk individuals in the second half of 2025.
Immunovia (IMMNOV) ha annunciato la pubblicazione del suo studio di scoperta nel Journal of Proteome Research, contrassegnandolo come il più grande studio di proteomica sul cancro del pancreas fino ad oggi. Lo studio ha identificato 41 biomarcatori proteici che mostrano una forte correlazione con l'adenocarcinoma duttale pancreatico (PDAC). La ricerca ha valutato circa 3.000 proteine in 329 campioni di sangue provenienti da pazienti con PDAC di Stadio I e II e da pazienti di controllo abbinati non affetti da PDAC.
Cinque di questi biomarcatori sono stati selezionati per il test di nuova generazione di Immunovia, che ha dimostrato un'eccellente sensibilità e specificità nel rilevare il cancro del pancreas in fase iniziale. L'azienda prevede di lanciare questo test per individui ad alto rischio nella seconda metà del 2025.
Immunovia (IMMNOV) anunció la publicación de su estudio de descubrimiento en el Journal of Proteome Research, marcándolo como el estudio de proteómica sobre cáncer de páncreas más grande hasta la fecha. El estudio identificó 41 biomarcadores de proteínas que correlacionan fuertemente con el adenocarcinoma ductal pancreático (PDAC). La investigación evaluó aproximadamente 3,000 proteínas en 329 muestras de sangre de pacientes con PDAC en Etapa I y II y pacientes de control emparejados sin PDAC.
Cinco de estos biomarcadores fueron seleccionados para la prueba de próxima generación de Immunovia, que demostró una excelente sensibilidad y especificidad en la detección del cáncer de páncreas en etapa temprana. La empresa planea lanzar esta prueba para individuos de alto riesgo en la segunda mitad de 2025.
Immunovia (IMMNOV)는 Journal of Proteome Research에 자사의 발견 연구 결과를 발표하며, 이를 지금까지의 가장 큰 췌장암 프로테오믹스 연구로 자리매김했습니다. 이 연구는 췌장 덕트 선암(PDAC)과 강한 상관관계를 가진 41개의 단백질 바이오마커를 식별했습니다. 연구에서는 I기 및 II기 PDAC 환자와 PDAC가 아닌 대조군 환자에서 채취한 329개의 혈액 샘플에서 약 3,000개의 단백질을 평가했습니다.
이들 바이오마커 중 5개는 Immunovia의 차세대 검사에 선택되었으며, 이 검사는 초기 췌장암을 감지하는 데 탁월한 민감도와 특이성을 보여주었습니다. 회사는 2025년 하반기에 고위험군을 위한 이 검사를 출시할 계획입니다.
Immunovia (IMMNOV) a annoncé la publication de son étude de découverte dans le Journal of Proteome Research, la qualifiant de plus grande étude en protéomique sur le cancer du pancréas à ce jour. L'étude a identifié 41 biomarqueurs protéiques qui présentent une forte corrélation avec l'adénocarcinome canalaire pancréatique (PDAC). La recherche a évalué environ 3 000 protéines dans 329 échantillons de sang provenant de patients PDAC de stade I et II et de patients témoins appariés non PDAC.
Cinq de ces biomarqueurs ont été sélectionnés pour le test de nouvelle génération d'Immunovia, qui a démontré une excellente sensibilité et spécificité dans la détection du cancer du pancréas à un stade précoce. La société prévoit de lancer ce test pour les personnes à haut risque dans la deuxième moitié de 2025.
Immunovia (IMMNOV) hat die Veröffentlichung seiner Entdeckungsstudie im Journal of Proteome Research angekündigt, und damit das größte proteomische Studium zu Bauchspeicheldrüsenkrebs bis heute markiert. Die Studie identifizierte 41 Protein-Biomarker, die stark mit dem duktalen Adenokarzinom der Bauchspeicheldrüse (PDAC) korrelieren. Die Forschung bewertete etwa 3.000 Proteine in 329 Blutproben von Patienten mit PDAC im Stadium I und II sowie von nicht-PDAC-gepaarten Kontrollpatienten.
Fünf dieser Biomarker wurden für den nächsten Test der Immunovia ausgewählt, der eine hervorragende Sensitivität und Spezifität bei der Erkennung von Bauchspeicheldrüsenkrebs im Frühstadium zeigte. Das Unternehmen plant, diesen Test in der zweiten Hälfte des Jahres 2025 für Hochrisikopatienten auf den Markt zu bringen.
- Publication in prestigious Journal of Proteome Research validates research quality
- Successfully identified 41 promising protein biomarkers for pancreatic cancer detection
- Next-generation test shows excellent sensitivity and specificity in clinical validation
- Clear commercialization timeline with launch planned for H2 2025
- Large addressable market with 1.8 million high-risk individuals in the USA
- Commercial revenue from new test not expected until H2 2025
Insights
The publication of Immunovia's discovery study in the Journal of Proteome Research represents a substantial scientific advancement in pancreatic cancer diagnostics. The study's scale - analyzing 3,000 proteins across 329 blood samples - and identification of 41 protein biomarkers specific to early-stage PDAC sets a new benchmark in proteomics research.
The selection of 5 biomarkers for the next-generation test demonstrates a strategic refinement process, optimizing for both sensitivity and specificity in early-stage detection. This is particularly important given that pancreatic cancer is typically diagnosed at late stages when survival rates are extremely poor. The validation of these markers in detecting Stage I and II pancreatic cancer could potentially transform early diagnosis paradigms.
The collaboration with Proteomedix AG and use of Olink multiplex technology adds credibility to the methodology. The planned 2025 commercial launch targeting high-risk individuals, estimated at 1.8 million people in the US alone, indicates significant market potential. However, successful commercialization will depend on clinical adoption, reimbursement policies and competition from other emerging diagnostic technologies.
The discovery study identified 41 promising protein biomarkers that were shown to strongly correlate with the presence of pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. These protein biomarkers demonstrated the ability to differentiate PDAC cases from non-PDAC controls. About 3,000 proteins were evaluated in 329 blood samples from Stage I and II PDAC and non-PDAC matched control patients using Olink multiplex technology and conventional immunoassays. Results of the discovery study, which was conducted jointly with Immunovia's research partner, Proteomedix AG, were first announced in November 2023.
Five of the 41 biomarkers were selected for inclusion in Immunovia's next-generation test in a subsequent model-development study. The high-performance test was later clinically validated in a study showing excellent sensitivity and specificity in detecting Stage I and II pancreatic cancer, as announced earlier this month.
"This discovery study provided a large number of promising biomarkers from which we built our high-accuracy next-generation test to detect early-stage pancreatic cancer," said Jeff Borcherding, CEO at Immunovia. "Publication of this study in the prestigious Journal of Proteome Research highlights the quality and novelty of our protein discovery program."
Journal of Proteome Research, published by the esteemed American Chemical Society, is recognized as a top-tier journal for research and reports on global protein analysis and function.
Immunovia plans to launch its next-generation test for detection of pancreatic cancer in high-risk individuals in the second half of 2025.
For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/immunovia-discovery-study-published-in-top-protein-research-journal-302337208.html
SOURCE Immunovia AB
FAQ
What are the key findings of Immunovia's (IMMNOV) pancreatic cancer discovery study?
When will Immunovia (IMMNOV) launch its next-generation pancreatic cancer test?
How many proteins did Immunovia's (IMMNOV) study evaluate?
What is the market size for Immunovia's (IMMNOV) pancreatic cancer test in the USA?
Which research partner collaborated with Immunovia (IMMNOV) on the discovery study?
